低分子APIの市場規模・シェア・成長分析 (種類別、メーカー別、用途別、地域別)：産業予測 (2024～2031年)

世界の低分子API (低分子原薬) の市場規模は、2022年に1,848億5,000万米ドルと評価され、2023年の1,949億米ドルから2031年には2,977億6,000万米ドルに拡大し、予測期間 (2024～2031年) に5.44%のCAGRで成長する見通しです。

世界の低分子医薬品原薬 (API) の状況は、慢性疾患の有病率の上昇や創薬開発への投資の増加に牽引され、大きな成長が見込まれています。先発医薬品の価格高騰はジェネリック医薬品へのシフトに拍車をかけており、低分子APIの需要は今後さらに高まると予想されます。さらに、API合成技術の進歩や低分子研究への投資の高まりは、APIサプライヤーに新たな機会をもたらしています。手頃な価格のがん治療薬に対するニーズの高まりも、世界規模での市場拡大を刺激すると予想されます。しかし、製造工程の複雑さ、製造コストの高さ、厳しい規制の枠組みといった課題は、今後の市場需要を阻害する可能性があります。それにもかかわらず、持続可能で継続的な製造手法への注目の高まりは、進化する市場環境の中で企業が革新を遂げ、成功するための潜在的な道を提供しています。このような要因の収束は、低分子APIセクターのダイナミックな未来を示唆しており、内在する課題を克服しながら新たな機会を活用する戦略的適応の必要性を強調しています。

目次

イントロダクション

• 調査の目的
• 定義
• 市場範囲

調査手法

• 情報調達
• 二次データソースと一次データソース
• 市場規模予測
• 市場の想定と制限

エグゼクティブサマリー

• 市場概要見通し
• 供給需要動向分析
• セグメント別機会分析

市場力学と見通し

• 市場力学
  • 促進要因
  • 機会
  • 抑制要因
  • 課題
• ポーターの分析

主な市場の考察

• 主な成功要因
• 競合の程度
• 主な投資機会
• 市場のエコシステム
• 親市場の分析
• PESTEL分析
• 規制情勢

低分子API市場：種類別

• 市場概要
• 合成
• バイオテクノロジー

低分子API市場：メーカー別

• 市場概要
• 社内
• アウトソーシング

低分子API市場：用途別

• 市場概要
• 心臓病学
• 腫瘍学
• 中枢神経系・神経学
• 整形外科
• 内分泌学
• 呼吸器科
• 消化器内科
• 腎臓学
• 眼科
• その他

低分子API市場：地域別

• 市場概要
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ
• 中東・アフリカ (MEA)
  • 湾岸協力会議 (GCC) 諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情勢

• 上位5社の比較
• 主要企業の市場ポジショニング (2023年)
• 主な市場企業が採用した戦略
• 市場における最近の活動
• 主要企業の市場シェア (2023年)

主要企業プロファイル

• Johnson Matthey (英国)
• Pfizer Inc. (米国)
• Nanjing King-Friend Biochemical Pharmaceutical Co. Ltd. (中国)
• Sanofi S.A. (フランス)
• Novartis AG (スイス)
• Bristol-Myers Squibb (米国)
• Boehringer Ingelheim GmbH (ドイツ)
• GlaxoSmithKline PLC (英国)
• GILEAD Sciences Inc. (米国)
• Albany Molecular Research Inc. (米国)
• AstraZeneca (英国)
• Merck & Co. Inc. (米国)
• BASF SE (ドイツ)
• Teva Pharmaceuticals (イスラエル)
• Hoffmann-La Roche Ltd. (スイス)
• Albemarle Corporation (米国)
• AbbVie (米国)
• Aurobindo Pharma (インド)
• Cambrex Corporation (米国)
• Dr. Reddy's Laboratories Ltd. (インド)
• Lonza (スイス)
• Merck KGaA (ドイツ)
• Siegfried Holding AG (スイス)
• Sun Pharmaceutical Industries Ltd. (インド)

Global Small Molecule API Market size was valued at USD 184.85 billion in 2022 and is poised to grow from USD 194.90 billion in 2023 to USD 297.76 billion by 2031, growing at a CAGR of 5.44% in the forecast period (2024-2031).

The global landscape for small molecule active pharmaceutical ingredients (APIs) is poised for significant growth, driven by the rising prevalence of chronic diseases and increased investments in drug discovery and development. The soaring prices of branded medications are fueling a shift towards generic drugs, which is anticipated to further enhance the demand for small molecule APIs in the coming years. Additionally, advancements in API synthesis technologies and heightened investment in small molecule research present new opportunities for API suppliers. The escalating need for affordable oncology medications is also expected to stimulate market expansion on a worldwide scale. However, challenges such as the complexity of manufacturing processes, high production costs, and stringent regulatory frameworks may hinder market demand moving forward. Nonetheless, a growing focus on sustainable and continuous manufacturing methodologies offers potential avenues for small molecule API companies to innovate and thrive in the evolving market landscape. This convergence of factors signals a dynamic future for the small molecule API sector, emphasizing the need for strategic adaptations to leverage emerging opportunities while navigating inherent challenges.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Small Molecule Api market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Small Molecule Api Market Segmental Analysis

Global Small Molecule API Market is segmented on the type, manufacturer, application, and region. By type, the market is segmented into Synthetic and Biotech. By manufacturer, the market is segmented into In-house and Outsourced. By application, the market is segmented into Cardiology, Oncology, CNS and Neurology, Orthopedic, Endocrinology, Pulmonology, Gastroenterology, Nephrology, Ophthalmology, and Others. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Driver of the Global Small Molecule Api Market

The rising prevalence of chronic disorders attributable to poor lifestyle choices is a significant market driver for the Global Small Molecule API market. As an increasing number of individuals grapple with conditions such as diabetes, cardiovascular diseases, and obesity, the demand for effective pharmaceutical interventions continues to surge. This growing need for targeted therapies propels the production and utilization of small molecule active pharmaceutical ingredients (APIs), known for their efficacy in treating a wide range of ailments. Consequently, the sustained expansion of healthcare expenditures and a focus on innovative drug development strategies further reinforce the momentum of the small molecule API market globally.

Restraints in the Global Small Molecule Api Market

The Global Small Molecule API market faces significant restraints due to the high manufacturing costs associated with the production of small molecule APIs. The process necessitates specialized equipment and facilities, which demand substantial capital investment. Additionally, the requirement for skilled professionals to operate such equipment further escalates operational costs. The reliance on expensive raw materials compounds these financial burdens, ultimately limiting the ability of manufacturers to scale production competitively. This cost-intensive aspect not only hinders market entry for new players but also restricts expansion opportunities for existing companies, thereby stifling overall market growth and development potential.

Market Trends of the Global Small Molecule Api Market

The Global Small Molecule API market is increasingly influenced by the rise of personalized medicine, driving a significant market trend towards tailored therapeutic solutions. As healthcare transitions to individualized treatment plans, small molecule API providers are optimizing their business models to address specific patient needs and niche markets. This shift is facilitating the development of innovative small molecule APIs that target unique biomarkers and genetic profiles, promising substantial returns for industry players. Consequently, this trend not only enhances treatment efficacy but also positions companies to thrive in a competitive landscape, thereby shaping the future of the pharmaceutical industry.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree of Competition
• Top Investment Pockets
• Ecosystem of the Market
• Parent Market Analysis
• PESTEL Analysis
• Regulatory Landscape

Small Molecule API Market, By Type

• Market Overview
• Synthetic
• Biotech

Small Molecule API Market, By Manufacturer

• Market Overview
• In-house
• Outsourced

Small Molecule API Market, By Application

• Market Overview
• Cardiology
• Oncology
• CNS and Neurology
• Orthopedic
• Endocrinology
• Pulmonology
• Gastroenterology
• Nephrology
• Ophthalmology
• Others

Small Molecule API Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Johnson Matthey (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nanjing King-Friend Biochemical Pharmaceutical Co. Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GILEAD Sciences Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Albany Molecular Research Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BASF SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceuticals (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Albemarle Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cambrex Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siegfried Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments